EF

Canon Announces New Cine and Broadcast Products, Pro Camcorders, PTZ Cameras, Cine Lens, Find More Info at B&H

Retrieved on: 
Wednesday, September 7, 2022
EOS, Waveform, EU, Somatosensory system, VR, LCD, Mark II, OSD, XC, HDMI, Lens, Timestamp, NEW, EF, PL, FHD, B&H, Smartphone, HDR, London, BBC Micro expansion unit, ITR, CR, Extender, Computer, ZEISS, 3G, Iris, SRT, Communication, OLED, Canon EOS C300 Mark II, PTZ, Remote control, UHD, Photography, Technology, CINE, Super 35, USB, Ethernet, Color, Metadata, XLR, Luts, EVF, ENG, CMOS, Blog, SDI, Camera, Cassette tape, Television, Canon

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- B&H is pleased to announce Canon's latest broadcast releases, including updated XA75, XA70, XA65, and XA60 professional camcorders, which feature new recording modes, enhanced usability, and improved EVFs and LCDs, while retaining the proven imaging specs and UHD 4K recording of their predecessors. Canon is also launching a VIXIA HF G70 compact camcorder; the CINE-SERVO 15-120mm T2.95-3.95 EF/PL-mount cinema lens; the EU-V3 Expansion Unit for the C300 Mark II and C500 Mark II cameras; the CR-N700 PTZ camera; and the DP-V2730 27" 4K reference monitor.

Key Points: 
  • The EVF has been updated, too, to a larger 0.36"OLED panel with 1.77m-dot resolution for clearer monitoring.
  • Moving over to the interchangeable lens portion of the broadcast and cine world, Canon has announced the impressive CINE-SERVO 15-120mm T2.95-3.95 lens, available in both EF and PL mount designs.
  • When you're in Manhattan, take a tour of the B&H Photo SuperStore , located at 420 Ninth Avenue.
  • With hundreds of products on display, the B&H Photo SuperStore is the place to test-drive and compare all the latest gear.

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction

Retrieved on: 
Wednesday, September 7, 2022
Neurology, Cardiology, Biotechnology, Oncology, General Health, Health, Genetics, Other Health, NYHA, Research, Safety, Pharmacokinetics, Northwest Biotherapeutics, NK, Neuregulin, D90, Toxicity, Immunoglobulin G, Heart failure, ADCC, Salubris Pharmaceuticals, Ipilimumab, Immunosuppression, Quality of life, Cohort, Patient, Therapy, Neurodegeneration, Șaeș, Journal of the American College of Cardiology, Biomarker, Clinical trial, D30, Pharmaceutical industry, Vaccine, Heart, EF

Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.

Key Points: 
  • Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.
  • We are also excited to now be recruiting for the first clinical trial with our IL15-CTLA4 antibody fusion, JK08, and we expect to share initial data in 2023.
  • JK08 was designed based on clinical studies from both individual molecules, which together portend synergistic effects in an antibody fusion construct.
  • A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 13) in Patients With Systolic Dysfunction and Heart Failure.

FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

Retrieved on: 
Saturday, August 27, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Cardiology, Death, European Society of Cardiology, EF, HF, University of Medicine 1, Yangon, The New England Journal of Medicine, CV, Patient, Pharmaceutical industry, Clothing

Detailed results from the DELIVER Phase III trial showed AstraZenecas FARXIGA (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo.

Key Points: 
  • Detailed results from the DELIVER Phase III trial showed AstraZenecas FARXIGA (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo.
  • Earlier heart failure with preserved ejection fraction trials have shown attenuation in the highest left ventricular ejection fraction but with dapagliflozin results are consistent across the ejection fraction range.
  • Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
  • Dapagliflozin Evaluation to Improve the LIVEs of Patients With Preserved Ejection Fraction Heart Failure; [cited 2022 Jul 26].

Eisenhower Fellowships Launches 2022 USA Justice Program

Retrieved on: 
Wednesday, August 17, 2022
Travel, Eisenhower Fellowships, Imprisonment, EF, Policy, Law enforcement, Constitution, Rewards for Justice Program, Education, U.S. Army Corps of Engineers, Europe District, Color, Fellows, Solution, Medicine, Defense, Online gambling, Management

PHILADELPHIA, Aug. 17, 2022 /PRNewswire-PRWeb/ -- Enforcing racial equality through the rule of law, President Dwight D. Eisenhower sent troops from the U.S. Army's 101 Airborne Division to Little Rock, Arkansas, in 1957 to protect the Constitutional right of nine Black students to attend a segregated all-white high school. More than six decades later, amid a national reckoning of relations between the races, Eisenhower Fellowships is advancing the legacy of its namesake with its inaugural 2022 USA Justice Program.

Key Points: 
  • More than six decades later, amid a national reckoning of relations between the races, Eisenhower Fellowships is advancing the legacy of its namesake with its inaugural 2022 USA Justice Program.
  • More than six decades later, amid a national reckoning of relations between the races, Eisenhower Fellowships is advancing the legacy of its namesake with its inaugural 2022 USA Justice Program.
  • For the biographies of the first USA Justice Program Fellows, please click HERE .
  • Since 1953, more than 2,400 mid-career leaders from 115 countries have benefitted from the unique experience of an Eisenhower Fellowship.

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Retrieved on: 
Tuesday, August 16, 2022
Health, Other Health, Other Science, General Health, Research, Science, Cardiology, EF, Multimedia, ABMD, Angina, Impella, Nasdaq, LVEF, Restore, Heart failure, PCI, Quality of life

View the full release here: https://www.businesswire.com/news/home/20220816005340/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220816005340/en/
    Restore EF is a prospective, multi-center study evaluating the best practices in contemporary PCI practice, including more complete revascularization.
  • The Restore EF study results add to the growing body of evidence demonstrating that Impella-supported high-risk PCI can lead to a more complete revascularization and considerable LVEF improvement, said Jason Wollmuth, MD, Restore EF study principal investigator and an interventional cardiologist at Providence Heart Institute.
  • The trial also found, during follow up after Protected PCI with Impella, patients had a 22% improvement in LVEF (p
  • Additional information about the Restore EF study, including case studies and interviews with the studys authors, is available on HeartRecovery.com .

Changing Your Perspective - Mindray Redefines the Possibilities of Point of Care Ultrasound (POCUS)

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, ZST, Intelligence, European Centre for Living Technology, Anesthesia, Simpson, Decision-making, Industry, Technology, EF, Emergency, Emergency medicine, Innovation Center station, Portrait, Critical care, TE, Solution, LV, Orientation, Innovation, Medical imaging, Medical device, Mindray, POCUS

MAHWAH, N.J., Aug. 9, 2022 /PRNewswire/ -- Mindray North America, a global leader and developer of healthcare technologies and solutions for ultrasound, patient monitoring, and anesthesia, announced the launch of a new product that is changing the perspective in the Point of Care Ultrasound (POCUS) market: the TE X Ultrasound System. The technology-rich system gives clinicians access to the most robust suite of artificial intelligence (AI)-powered Smart Tools available today and is powered by Mindray's proprietary software-based beamformer Zone Sonography Technology+ (ZST+). This new product has a leading industrial design with an unrivaled 23.8-inch rotatable, full touchscreen display that supports both landscape and portrait orientation for easy adaptability to any clinical environment, and an industry-first wireless transducer that connects to the TE X System or can be used independently with a mobile device.   

Key Points: 
  • With a leading industrial design & suite of AI-powered Smart Tools, Mindray's TE X redefines the possibilities of POCUS.
  • Six years ago, Mindray disrupted the POCUS industry with the launch of the first fully touch-based ultrasound, the TE7 Ultrasound System .
  • Last year, Mindray did it again and set a new standard for POCUS with the TE7 Max Ultrasound System .
  • "The TE Series Ultrasound Family continues to push the boundaries of Point of Care Ultrasound," said Wayne Quinn, President of Mindray North America.

RED DIGITAL CINEMA Releases the V-RAPTOR XL 8K VV Cinema Camera and Accessories, Learn and Preorder at B&H

Retrieved on: 
Wednesday, August 3, 2022
Technology, Photography, Entertainment, Film & Motion Pictures, Blog, Red Touch Media, ND, USB-C, XLR, Computer, 3D LUT, USB, EF-S, CMOS, Titanium, RMI, AC, TB, DCI, LCD, Somatosensory system, Photography, XL, PDAF, Gold, EF, CFexpress, PL, Apple ProRes, 3A, B&H, Camera, Video game console

The XL expands its feature set by adding an interchangeable PL mount with an optional EF mount, widening your cinema lens options.

Key Points: 
  • The XL expands its feature set by adding an interchangeable PL mount with an optional EF mount, widening your cinema lens options.
  • It also features a versatile internal electronic ND filter that ranges from 2 to 7 stops, selectable at 1/3-, -, or 1-stop intervals.
  • Other features include 5-pin audio input ports, built-in dual microphones, 3D LUT import, and wired control via USB Type-C.
  • With thousands of products on display, the B&H Photo SuperStore is the place to test-drive and compare all the latest gear.

Eisenhower Fellowships Selects Fall 2022 Global Fellows

Retrieved on: 
Tuesday, August 2, 2022
Goal, Stern Global Programs, Carbon, Environment, Fear, Defense, Private sector, Hospital, Woman, Violence, Culture, Government, Genetics, Travel, Eisenhower Fellowships, Music, EF, Society, City, Medicine, Management

PHILADELPHIA, Aug. 2, 2022 /PRNewswire-PRWeb/ -- Twenty-five ascendant leaders from 23 countries have been selected for Eisenhower Fellowships' prestigious 2022 Global Program, six weeks of intensive, mid-career development in the United States this fall in pursuit of groundbreaking projects and enlightening exchanges with critical thinkers in their fields.

Key Points: 
  • Twenty-five ascendant leaders from 23 countries have been selected for Eisenhower Fellowships' prestigious 2022 Global Program, six weeks of intensive, mid-career development in the United States this fall in pursuit of groundbreaking projects and enlightening exchanges with critical thinkers in their fields.
  • PHILADELPHIA, Aug. 2, 2022 /PRNewswire-PRWeb/ --Twenty-five ascendant leaders from 23 countries have been selected for Eisenhower Fellowships' prestigious 2022 Global Program, six weeks of intensive, mid-career development in the United States this fall in pursuit of groundbreaking projects and enlightening exchanges with critical thinkers in their fields.
  • Drawn from across Asia, Africa, Europe, Latin America and Australia, the 2022 Global Fellows are private and public sector leaders engaged in addressing some of the most pressing issues of our times.
  • Since 1953, more than 2,400 mid-career leaders from 115 countries have benefitted from the unique experience of an Eisenhower Fellowship.

AM Best Affirms Credit Ratings of ERIKA Försäkringsaktiebolag (publ)

Retrieved on: 
Wednesday, July 13, 2022
Insurance, Professional Services, ALL, News, EF Education First, Risk management, AM, Travel, Insurance, Credit, AM Best, Growth, Industry, EF

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of a- (Excellent) of ERIKA Frskringsaktiebolag (publ) (Erika) (Sweden).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of a- (Excellent) of ERIKA Frskringsaktiebolag (publ) (Erika) (Sweden).
  • AM Best expects Erika to remain profitable in 2022, despite some ongoing impact on gross written premium from pandemic-related travel limitations.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • For information on the proper use of Bests Credit Ratings, Bests Performance Assessments, Bests Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Bests Ratings & Assessments .

LBank Exchange Will List LuckyCoin (LKC) on July 4, 2022

Retrieved on: 
Sunday, July 3, 2022
LuckyCoin, Takeoff, UAM, Attention, Marketing, EVTOL, Technology, Time, Urban air mobility, EF, Nature, VTOL, Cryptocurrency, Online gambling, Phoenix

Internet City, Dubai--(Newsfile Corp. - July 3, 2022) - LBank Exchange, a global digital asset trading platform, will list LuckyCoin (LKC) on July 4, 2022.

Key Points: 
  • Internet City, Dubai--(Newsfile Corp. - July 3, 2022) - LBank Exchange, a global digital asset trading platform, will list LuckyCoin (LKC) on July 4, 2022.
  • For all users of LBank Exchange, the LKC/USDT trading pair will be officially available for trading at 18:00 (UTC+8) on July 4, 2022.
  • Its native token LKC will be listed on LBank Exchange at 18:00 (UTC+8) on July 4, 2022, to further expand its global reach and help it achieve its vision.
  • The LKC token will be listed on LBank Exchange at 18:00 (UTC+8) on July 4, 2022, investors who are interested in LuckyCoin investment can easily buy and sell LKC token on LBank Exchange by then.